JPS6151585B2 - - Google Patents
Info
- Publication number
- JPS6151585B2 JPS6151585B2 JP952179A JP952179A JPS6151585B2 JP S6151585 B2 JPS6151585 B2 JP S6151585B2 JP 952179 A JP952179 A JP 952179A JP 952179 A JP952179 A JP 952179A JP S6151585 B2 JPS6151585 B2 JP S6151585B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- formula
- solution
- ethyl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- -1 nicotinoyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000000434 field desorption mass spectrometry Methods 0.000 description 3
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BDJNKRWNBVYPCQ-AWEZNQCLSA-N C(C1=CN=CC=C1)(=O)N(C(=O)[C@H](O)C(C)(C)CO)CCC(NCCS)=O Chemical class C(C1=CN=CC=C1)(=O)N(C(=O)[C@H](O)C(C)(C)CO)CCC(NCCS)=O BDJNKRWNBVYPCQ-AWEZNQCLSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- QDXBVEACAWKSFL-UHFFFAOYSA-N ethenethiol Chemical group SC=C QDXBVEACAWKSFL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP952179A JPS55102567A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP952179A JPS55102567A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55102567A JPS55102567A (en) | 1980-08-05 |
| JPS6151585B2 true JPS6151585B2 (US20110232667A1-20110929-C00004.png) | 1986-11-10 |
Family
ID=11722562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP952179A Granted JPS55102567A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55102567A (US20110232667A1-20110929-C00004.png) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61143289U (US20110232667A1-20110929-C00004.png) * | 1985-02-25 | 1986-09-04 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1318254C (en) * | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
-
1979
- 1979-01-30 JP JP952179A patent/JPS55102567A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61143289U (US20110232667A1-20110929-C00004.png) * | 1985-02-25 | 1986-09-04 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55102567A (en) | 1980-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111961057A (zh) | 一种α构型核苷及其在治疗猫冠状病毒感染的应用 | |
| TWI714566B (zh) | 軸手性異構體及其製備方法和製藥用途 | |
| KR20200010483A (ko) | Fxr 수용체 작용제로서 락탐 화합물 | |
| JPH07502265A (ja) | 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体 | |
| JPS59163400A (ja) | ウルソデソキシコ−ル酸硫酸エステルのナトリウム塩 | |
| CH387636A (fr) | Procédé de préparation de nouvelles phénothiazines | |
| JPS6253966A (ja) | 新規ピリジン誘導体 | |
| JPS6151585B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6312063B2 (US20110232667A1-20110929-C00004.png) | ||
| JPH0243749B2 (US20110232667A1-20110929-C00004.png) | ||
| US5061711A (en) | Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters | |
| JPS63295561A (ja) | ２−キノロン誘導体 | |
| US4024280A (en) | Abietanilides, their production and use | |
| CA3171987A1 (en) | Crystalline forms of a farnesoid x receptor agonist | |
| JP7244487B2 (ja) | ステロイド系誘導体ｆｘｒアゴニストの結晶又は非晶質、その製造方法及び使用 | |
| JPH0560478B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6157828B2 (US20110232667A1-20110929-C00004.png) | ||
| Buck et al. | β-Phenylethylamine Derivatives. 1 Tertiary and Quaternary Salts | |
| JPH03188088A (ja) | 新規リゾホスファチジルセリン | |
| JPH01249733A (ja) | ペンタン二酸誘導体の代謝物質 | |
| AU2019388805B2 (en) | Solid form, crystalline form, and crystal form A of FXR agonist, and preparation method therefor and application thereof | |
| JPS637558B2 (US20110232667A1-20110929-C00004.png) | ||
| JPH0370700B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS631938B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS5892699A (ja) | ３′′′−デヒドロ−カルデノリド−トリジギトキソシド−オキシム、その製法及び該化合物を含有する心不全用治療薬 |
